Previous studies have shown that DUXAP10 could promote tumor progression in non-small cell lung cancer [15], colorectal cancer [16], gastric cancer [17], pancreatic cancer [18], esophageal squamous cell carcinoma [19], and bladder cancer [20]. Here, DUXAP10 is linked to urinary bladder carcinoma.